Respiratory syncytial virus non-structural protein 2 (NS2) (NS2)

The Respiratory syncytial virus (RSV) non-structural protein 2 (NS2) is a critical viral factor responsible for suppressing the host's innate immune system during infection. It functions primarily as an interferon (IFN) antagonist by facilitating the proteasome-mediated degradation of Signal Transducer and Activator of Transcription 1 (STAT1) and by binding to Retinoic Acid-Inducible Gene I (RIG-I) to prevent the activation of antiviral signaling pathways (UniProt P04545; PubMed: 19144714). These actions allow the virus to replicate efficiently by delaying the host's ability to mount an effective cellular defense. NS2 also influences the shedding of infected airway epithelial cells, a process that contributes to the physical obstruction of small airways seen in clinical RSV cases such as bronchiolitis (PubMed: 22438547). While there are currently no approved small-molecule drugs that directly inhibit NS2, the protein is a central target in the design of live-attenuated vaccines. By deleting or mutating the NS2 gene, researchers can create attenuated virus strains that are safe for vaccination but still capable of eliciting a robust immune response (PubMed: 30115711). Consequently, NS2 remains a significant focus for both vaccine development and the discovery of novel antiviral therapies aimed at restoring host immunity.

Other names

Non-structural protein 2RSV NS2NS2 proteinProtein NS2

Inhibition of host innate immune response through proteasomal degradation of STAT1 and interference with RIG-I signaling pathways.